Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

Finerenone Receives FDA Approval for Treatment of Adults With CKD Associated With T1D

17 September 2026 · By · Wire by Fusion42

Published

17 September 2026

Topic

opportunities

◆ Sectors

Drug Discovery

◆ Geography

United States

◆ Source

Read at pharmacytimes.com →

◆ Verified

Fusion42 · 18 September 2026 · Fusion42 review

The FDA approved finerenone for treatment of adults with chronic kidney disease (CKD) associated with type 1 diabetes, based on positive results from the phase 3 FINE-ONE trial showing significant reduction in albuminuria.

This Wire brief sits within Fusion42's coverage of Drug Discovery, and 5 sources have reported it between 17 Sep 2026 and 22 Sep 2026.

◆ ◆ The Wire takeaway

You can now pursue the T1D-associated CKD market with finerenone-based therapies that reduce kidney damage markers. The need for structured monitoring of potassium and kidney function creates a service and compliance opportunity around this new treatment.

◆ Coverage

5 sources · first reported 17 Sep 2026 · latest 22 Sep 2026

◆ Related on Wire

◆ Topics

Drug Discoveryfda-approvalckdtype-1-diabetesfinerenoneclinical-trial